Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation

Journal of Immunotherapy

Volumn 22, Issue 6, 1999, Pages 525-538

  Krup, Oliver C ^a   Kroll, Ina ^a   Bose, Guido ^a   Falkenberg, Frank W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cytokine depots; Cytokine dose; Liposomeencapsulated IL 2; Tumor vaccines

Indexed keywords

CYTOKINE; IMMUNOLOGICAL ADJUVANT; LATEX; LIPOSOME; RECOMBINANT INTERLEUKIN 2; TUMOR VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR IMMUNITY; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; DELAYED-ACTION PREPARATIONS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; KIDNEY NEOPLASMS; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SPLEEN; VACCINATION;

EID: 0032726602     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199911000-00007     Document Type: Article

References (17)

1. Forni G, Cavallo F, Consalvo M, et al. Molecular approaches to cancer immunotherapy. Review. Cytokines Mol Ther 1995; 1:225-48.
2. Musiani P, Modesti A, Giovarelli M, et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. Viewpoint. Immunol Today 1996;18:32-36.
3. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL. Interleukin-2 dependent activation of tumor-specific cytotoxic T-lymphocytes in vitro. Eur J Immunol 1991;21:851-4.
4. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
5. Falkenberg FW, Reimer M. Liposome-encapsulated cytokines covalently coupled to tumor cells: an alternative to gene-transfected tumor cells as vaccines? Vaccine Res 1995;4:105-11.
6. Krup OC, Falkenberg FW. Vaccination against the mouse B16 melanoma: irradiated tumor cells mixed with liposome-encapsulated IL-2 as an alternative to IL-2 gene transfected tumor cells. In: Altmeyer P, Hoffmann K, Stiicker M, eds. Skin cancer and UV radiation. Berlin and Heidelberg: Springer-Verlag, 1997:1242-9.
7. Anderson PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, Bostrom B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother 1991;12:19-31.
8. Colombo MP, Lombardi L, Stoppacciaro A, et al. Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neurophil-mediated tumor inhibition in vivo. J Immunol 1992;149:113-9.
9. Jaffee EM, Thomas MC, Huang AY-C, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother 1996;19:176-83.
10. Schmidt W, Schweighoffer T, Herbst E, et al. Cancer vaccines: the interleukin dosage effect. Proc Natl Acad Sci USA 1995;92: 4711-4.
11. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
12. Kedar E, Braun E, Rutkowski Y, Emanuel N, Barenholz Y. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J Immunother 1994;16:115-24.
13. Andersen PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, Bostrom B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother 1992;12:19-31.
14. Gershman N, Johnston D, Bystryn J-C. Potentiation of melanoma vaccine immunogenicity by interleukin 2 liposomes. Vaccine Res 1994;3:83-92.
15. Hoffmann J, Bimmler M, Lasch J, Giesemann P. Tumoristatic activity of liposomes reconstituted from tumor associated antigens and interleukin 2 for immunotherapy of fibrosarcomas in Balb/c mice. J Liposome Res 1993;3:107-21.
16. Adler A, Schachter J, Barenholz Y, et al. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects. Cancer Biother 1995;10:293-306.
17. Sencer SF, Rich ML, Katsanis E, Ochoa AC, Anders PM. Antitumor vaccine adjuvant effects of IL-2 liposomes in mice immunized against Mca-102 sarcoma. Eur Cytokine Netw 1991;2:311-8.